Protalix BioTherapeutics Stock Forecast, Price & News

+0.02 (+0.92 %)
(As of 06/14/2021 02:08 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume139,681 shs
Average Volume2.28 million shs
Market Capitalization$99.38 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Protalix BioTherapeutics logo

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.31 out of 5 stars

Medical Sector

853rd out of 2,099 stocks

Biological Products, Except Diagnostic Industry

123rd out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Protalix BioTherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

Is Protalix BioTherapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Protalix BioTherapeutics stock.
View analyst ratings for Protalix BioTherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Protalix BioTherapeutics?

Wall Street analysts have given Protalix BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Protalix BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Protalix BioTherapeutics' next earnings date?

Protalix BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Protalix BioTherapeutics

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) posted its quarterly earnings results on Thursday, May, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.03.
View Protalix BioTherapeutics' earnings history

When did Protalix BioTherapeutics' stock split? How did Protalix BioTherapeutics' stock split work?

Protalix BioTherapeutics's stock reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix BioTherapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PLX?

1 brokerages have issued 1 year price objectives for Protalix BioTherapeutics' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Protalix BioTherapeutics' stock price to reach $7.00 in the next year. This suggests a possible upside of 221.1% from the stock's current price.
View analysts' price targets for Protalix BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protalix BioTherapeutics' key executives?

Protalix BioTherapeutics' management team includes the following people:
  • Mr. Dror Bashan, Pres, CEO & Director (Age 54, Pay $404.53k)
  • Mr. Eyal Rubin M.B.A., Sr. VP, CFO, Treasurer & Corp. Sec. (Age 45, Pay $323.63k)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 57, Pay $305.87k)
  • Dr. Einat Brill-Almon, Sr. VP & Chief Devel. Officer (Age 61, Pay $328.26k)
  • Ms. Dafna Shelly M.Sc., MBA, VP of HR

Who are some of Protalix BioTherapeutics' key competitors?

What other stocks do shareholders of Protalix BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BioLineRx (BLRX), VBI Vaccines (VBIV), Sangamo Therapeutics (SGMO), Verastem (VSTM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP).

What is Protalix BioTherapeutics' stock symbol?

Protalix BioTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Who are Protalix BioTherapeutics' major shareholders?

Protalix BioTherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Psagot Investment House Ltd. (6.82%), DAFNA Capital Management LLC (2.65%), Renaissance Technologies LLC (1.12%), Phoenix Holdings Ltd. (0.54%), D.A. Davidson & CO. (0.29%) and Schonfeld Strategic Advisors LLC (0.20%). Company insiders that own Protalix BioTherapeutics stock include Aharon Schwartz and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Protalix BioTherapeutics

Which institutional investors are buying Protalix BioTherapeutics stock?

PLX stock was acquired by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., DAFNA Capital Management LLC, Phoenix Holdings Ltd., D.A. Davidson & CO., Schonfeld Strategic Advisors LLC, Laurion Capital Management LP, Virtu Financial LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Protalix BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protalix BioTherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $2.18.

How much money does Protalix BioTherapeutics make?

Protalix BioTherapeutics has a market capitalization of $98.93 million and generates $62.90 million in revenue each year. The company earns $-6,520,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Protalix BioTherapeutics have?

Protalix BioTherapeutics employs 207 workers across the globe.

What is Protalix BioTherapeutics' official website?

The official website for Protalix BioTherapeutics is www.protalix.com.

Where are Protalix BioTherapeutics' headquarters?

Protalix BioTherapeutics is headquartered at 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel.

How can I contact Protalix BioTherapeutics?

Protalix BioTherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.